[CAS NO. 129580-63-8] Satraplatin

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [129580-63-8]

Catelog

HY-17576

Brand

MCE

CAS

129580-63-8

DESCRIPTION [129580-63-8]

Overview

MDL	-
Molecular Weight	500.28
Molecular Formula	C10H22Cl2N2O4Pt
SMILES	[Cl-][Pt+4]([O-]C(C)=O)([O-]C(C)=O)([Cl-])([NH3])[NH2]C1CCCCC1

For research use only. We do not sell to patients.

Summary

Satraplatin is an alkylating agent, with potent antitumor effect.

In Vitro

Satraplatin needs to avoid light in the solution, and it is unstable in the alkaline state but stable in the acidic state.
Satraplatin has potent antitumor activity. Satraplatin combined with dichloroacetate (DCA) inhibits UMC-11 cells with an IC ₅₀ of 1.36 ± 0.11 μM ^[1] . Satraplatin also suppresses CDDP-resistant (KB-R) cells (IC ₅₀ , 7.04 μM), and causes G2/M arrest in KB-R cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00265655	Agennix	Metastatic Breast Cancer	November 2005	Phase 2
NCT00499694	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Prostate Cancer	October 2007	Not Applicable
NCT00125411	Agennix	Tumors	March 2007	Phase 1
NCT03258320	Shanghai Jiao Tong University School of Medicine\|Fudan University\|Qilu Hospital of Shandong University	Prostate Cancer Patients	January 2015	Phase 1
NCT01259479	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Solid Tumors\|Brain Tumors\|Brain Metastases	December 3, 2010	Phase 1
NCT00329329	Agennix	Malignancies	May 2006	Phase 1
NCT01220284	Southern Europe New Drug Organization\|Agennix\|Pierre Fabre Laboratories	Advanced Solid Tumors	February 2008	Phase 1
NCT00093132	Agennix	Carcinoma, Non-small Cell Lung\|Lung Cancer	August 2004	Phase 1\|Phase 2
NCT00268970	Agennix	Non-small Cell Lung Cancer	December 2005	Phase 2
NCT00634647	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Prostate Cancer\|Genetic Polymorphism	February 19, 2008	Phase 2
NCT00450970	Agennix	Prostate Cancer	February 2007	Phase 3
NCT01289067	William K. Oh\|Prostate Cancer Foundation\|Icahn School of Medicine at Mount Sinai	Prostate Cancer	December 2010	Phase 2
NCT00473720	Yale University\|Agennix	Advanced Cancers	May 2007	Phase 1
NCT00480623	Agennix	Prostate Cancer	May 2007	Phase 1
NCT00370383	Agennix	Lung Cancer	July 2006	Phase 2
NCT00313456	Agennix	Tumors\|Prostate Cancer	March 2006	Phase 1
NCT00069745	Agennix	Prostate Cancer\|Hormone Refractory Prostate Cancer	September 2003	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMF : 10 mg/mL ( 19.99 mM ; ultrasonic and adjust pH to 1 with HCl ; DMSO can inactivate Satraplatin's activity)

Ethanol : < 1 mg/mL (insoluble ; DMSO can inactivate Satraplatin's activity)

H ₂ O : < 0.1 mg/mL (insoluble ; DMSO can inactivate Satraplatin's activity)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9989 mL	9.9944 mL	19.9888 mL
5 mM	0.3998 mL	1.9989 mL	3.9978 mL
10 mM	0.1999 mL	0.9994 mL	1.9989 mL

* Please refer to the solubility information to select the appropriate solvent.

References

Synonyms

Platinum, bis(acetato-κO)amminedichloro(cyclohexanamine)-, (OC-6-43)-

Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)-

Cyclohexanamine, platinum complex

JM 216

Satraplatin

BMY 45594

POplat

BMS 182751